Establishment of primary xenograft model from newly characterized patient extrauterine carcinosarcoma
case-report
OA: bronze
public-domain-us
AI-generated summary
Primary carcinosarcoma cells successfully generated tumorigenesis in mice, retaining original characteristics and showing susceptibility to doxorubicin and nilotinib.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BACKGROUND AND OBJECTIVE: The aim of this study was to characterize primary cells from extrauterine carcinosarcoma (CS) and to establish a primary CS xenograft mouse model.
METHODS: Primary cells were isolated from a patient with CS and cultured in vitro. Primary CS cells were verified for their ability to consecutively generate tumorigenesis in NOD/SCID mice. The properties of xenograft tumor and explants cells were investigated by immunohistochemistry, cytogenetic, and FACS analysis. Anticancer drug susceptibility of primary CS was analyzed using CCK-8.
RESULTS: Primary CS cells greater than 27 passages in vitro showed an ability of a series of xenograft tumorigenesis in vivo having the same marker expression and cytogenetic character as that of original tumor. In addition, explants of xenograft tumors retained their original characteristics in the in vitro culture system. Finally, the analysis of the susceptibility to anticancer drug revealed that primary CS cells were susceptible to both doxorubicin and nilotinib, which are tyrosine kinase inhibitors.
CONCLUSIONS: The primary CS cells and the primary CS xenograft tumorigenesis introduce a new therapeutic model for targeting cancer and also explore a deeper understanding of generation of the tumor itself.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-10-04T09:26:46.659050+00:00
- pubmed
- last seen: 2026-05-13T22:18:47.062786+00:00
- unpaywall
- last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine